Prospira ENT Announces Convertible Note Financing Round to Advance Allergy Treatment Innovation

San Francisco, CA – March 1st 2025 – Prospira ENT, a biotech company pioneering long-lasting allergy relief through a bioabsorbable mometasone implant, has announced the launch of a convertible note financing round to support the next phase of its development. The company is seeking to raise $3 million to advance preclinical research, optimize device design, and prepare for first-in-human clinical trials.

Prospira’s innovative bioabsorbable implant delivers up to six months of relief for patients suffering from moderate to severe seasonal allergic rhinitis. With a clear regulatory pathway via the 505(b)(2) drug approval process and identified reimbursement codes, Prospira is positioned to disrupt the $24 billion allergy market.

“We are excited to launch this financing round, which will allow us to complete critical preclinical studies and move one step closer to bringing our breakthrough allergy treatment to patients,” said Justin Chickles, CEO of Prospira ENT. “This funding will accelerate our work with regulatory agencies, support manufacturing scale-up, and position us for human clinical trials.”

Prospira ENT invites angel investors, venture capital firms, and strategic partners to participate in this opportunity to support next-generation allergy treatment. For more information on the financing round, please contact prospiraent@gmail.com